Time from Immune Checkpoint Inhibitor to Sotorasib Use Correlates with Risk of Hepatotoxicity in Non-small Cell Lung Cancer

S. Rakshit,R. Bansal,A. Potter,R. Manochakian,Y. Lou,Y. Zhao,V. Ernani,P. Savvides,A. Schwecke,N. Moffett,C. Hocum,K. Leventakos,A. Adjei,R. Marks,J. Molina,A. Mansfield,A. Dimou

JOURNAL OF THORACIC ONCOLOGY（2022）

引用 1|浏览5

暂无评分

摘要

One-third of patients developed grade 3 or higher sotorasib induced hepatotoxicity. Risk of hepatotoxicity was higher in patients who received sotorasib within 90 days of ICI treatment.

查看译文

关键词

Sotorasib, hepatotoxicity, Immune checkpoint inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要